Question: Over the past two years, I’ve experienced increased difficulties and symptoms, with one of the most challenging being fatigue and weakness. I feel physically limited and unable to function like others. Carrying a backpack or even light bags is difficult, affecting my balance and physical strength. Walking feels heavy, my eyes feel tired, and overall, I feel weak. I struggle to interact with others, realizing I can’t keep up without being perceived as weaker or needing help. Can this be improved? Could it be related to Ocrevus?

Answer:
Fatigue and general weakness are common complaints among MS patients, significantly affecting daily life and functioning.

There are medications, such as Modafinil or Amantadine, that may help alleviate fatigue. However, studies have shown no significant difference between these medications and placebo. It’s important to consider that some of these symptoms might stem from sleep disturbances common in MS patients. Diagnosing and treating any sleep disorder can potentially improve your condition.

Regarding Ocrevus, some patients report feeling a decline in symptoms about one to one and a half months before their next dose. If this might be the case, it’s worth discussing with your healthcare provider.

Question: I’m 67 and have never been vaccinated. What is your opinion on the flu vaccine?

Answer:
The flu vaccine has been proven effective for the general population, and it is especially important for individuals with chronic illnesses, including MS. Vaccination can help prevent flu infections that might trigger relapses or exacerbate existing symptoms. Consult your physician to determine the best timing for vaccination based on your treatment regimen.

Question: Are there any studies on drugs for repairing the myelin sheath, and have any been FDA-approved?

Answer:
Current treatments can somewhat support the remyelination process, but as of now, there is no FDA-approved drug specifically designed for this purpose.

Some experimental treatments in research have shown partial effects on remyelination, but many have only reached phase 2 trials and not advanced to phase 3.

Existing treatments primarily focus on preventing relapses. Some penetrate brain tissue and act on a variety of cells involved in the disease process. Future research may bring therapies targeting the underlying mechanisms of MS and providing new solutions for patients.